{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:25:50Z","timestamp":1786987550777,"version":"build-2736575974"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015652","name":"Barts Charity","doi-asserted-by":"publisher","award":["Cardiovascular Programme Award G00913"],"award-info":[{"award-number":["Cardiovascular Programme Award G00913"]}],"id":[{"id":"10.13039\/100015652","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015652","name":"Barts Charity","doi-asserted-by":"publisher","award":["MGU0401"],"award-info":[{"award-number":["MGU0401"]}],"id":[{"id":"10.13039\/100015652","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015652","name":"Barts Charity","doi-asserted-by":"publisher","award":["C16420\/A18066"],"award-info":[{"award-number":["C16420\/A18066"]}],"id":[{"id":"10.13039\/100015652","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UKRI | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R01065X\/2"],"award-info":[{"award-number":["MR\/R01065X\/2"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023233","name":"NIHR | National Institute for Health and Care Research Applied Research Collaboration Oxford and Thames Valley","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023233","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["EP\/Y027698\/1"],"award-info":[{"award-number":["EP\/Y027698\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2025,8,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Activating mutations of Src homology-2 domain-containing protein tyrosine phosphatase-2 (Shp2) cause multiple childhood conditions for which there is an unmet therapeutic need, including juvenile myelomonocytic leukemia (JMML) and Noonan syndrome. SFX-01, an \u03b1-cyclodextrin-stabilized sulforaphane complex currently in clinical development, covalently adducts cysteine residues. Using unbiased proteomics, its protein targets were identified, including Shp2. SFX-01 induced an inhibitory dithiolethione modification at the Shp2 active site cysteine. Importantly, in a transgenic mouse model of human Noonan syndrome with hyperactive D61G Shp2, SFX-01 concomitantly normalized their phosphatase activity and myeloid cell count. Furthermore, SFX-01 also attenuated JMML human patient-derived hematopoietic stem cell proliferation that was linked to STAT1 signaling and decreased cyclin D1 expression, resulting in cell-cycle arrest. We conclude that SFX-01 is an activating mutant Shp2 inhibitor and may offer beneficial effects in patients with JMML or Noonan syndrome.<\/jats:p>","DOI":"10.1038\/s44321-025-00267-7","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T15:14:19Z","timestamp":1752160459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2"],"prefix":"10.1038","volume":"17","author":[{"given":"Hyun-Ju","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H","family":"Switzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0543-7397","authenticated-orcid":false,"given":"Eleni","family":"Louka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4115-6135","authenticated-orcid":false,"given":"Rebecca L","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0394-7000","authenticated-orcid":false,"given":"Oleksandra","family":"Prysyazhna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewald","family":"Schroder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Fernandez-Caggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0828-0305","authenticated-orcid":false,"given":"Daniel Simoes","family":"de Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seda","family":"Eminaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5172-0935","authenticated-orcid":false,"given":"Xiaoke","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Lynham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0856-5121","authenticated-orcid":false,"given":"Valle","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4549-4476","authenticated-orcid":false,"given":"Katiuscia","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6361-4291","authenticated-orcid":false,"given":"Vinothini","family":"Rajeeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3426-2274","authenticated-orcid":false,"given":"Pedro R","family":"Cutillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J","family":"Mead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0748-2367","authenticated-orcid":false,"given":"Philip","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"267_CR1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1074\/mcp.M112.017483","volume":"11","author":"MP Alcolea","year":"2012","unstructured":"Alcolea MP, Casado P, Rodr\u00edguez-Prados J-C, Vanhaesebroeck B, Cutillas PR (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance*. Mol Cell Proteom 11:453\u2013466","journal-title":"Mol Cell Proteom"},{"key":"267_CR2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199404143301501","volume":"330","author":"Alpha-Tocopherol BCCPSG","year":"1994","unstructured":"Alpha-Tocopherol BCCPSG (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029\u20131035","journal-title":"N Engl J Med"},{"key":"267_CR3","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nm1084","volume":"10","author":"T Araki","year":"2004","unstructured":"Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL, Yang W, Pao LI, Gilliland DG, Epstein JA et al (2004) Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 10:849\u2013857","journal-title":"Nat Med"},{"key":"267_CR4","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1542\/peds.2013-3251","volume":"133","author":"A Artoni","year":"2014","unstructured":"Artoni A, Selicorni A, Passamonti SM, Lecchi A, Bucciarelli P, Cerutti M, Cianci P, Gianniello F, Martinelli I (2014) Hemostatic abnormalities in Noonan syndrome. Pediatrics 133:e1299\u20131304","journal-title":"Pediatrics"},{"key":"267_CR5","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3390\/cancers14092129","volume":"14","author":"JE Bauman","year":"2022","unstructured":"Bauman JE, Hsu CH, Centuori S, Guillen-Rodriguez J, Garland LL, Ho E, Padi M, Bageerathan V, Bengtson L, Wojtowicz M et al (2022) Randomized crossover trial evaluating detoxification of tobacco carcinogens by broccoli seed and sprout extract in current smokers. Cancers 14:2129","journal-title":"Cancers"},{"key":"267_CR6","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1182\/blood.2019001543","volume":"134","author":"M Bellio","year":"2019","unstructured":"Bellio M, Garcia C, Edouard T, Voisin S, Neel BG, Cabou C, Valet P, Mori J, Mazharian A, Senis YA et al (2019) Catalytic dysregulation of SHP2 leading to Noonan syndromes affects platelet signaling and functions. Blood 134:2304\u20132317","journal-title":"Blood"},{"key":"267_CR7","doi-asserted-by":"crossref","first-page":"8816","DOI":"10.1158\/0008-5472.CAN-04-1923","volume":"64","author":"M Bentires-Alj","year":"2004","unstructured":"Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ et al (2004) Activating mutations of the Noonan syndrome-associated SHP2\/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64:8816\u20138820","journal-title":"Cancer Res"},{"key":"267_CR8","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1073\/pnas.0804336105","volume":"105","author":"B Boivin","year":"2008","unstructured":"Boivin B, Zhang S, Arbiser Jack L, Zhang Z-Y, Tonks Nicholas K (2008) A modified cysteinyl-labeling assay reveals reversible oxidation of protein tyrosine phosphatases in angiomyolipoma cells. Proc Natl Acad Sci USA 105:9959\u20139964","journal-title":"Proc Natl Acad Sci USA"},{"key":"267_CR9","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/nutrit\/nuaa129","volume":"79","author":"L Cardozo","year":"2021","unstructured":"Cardozo L, Alvarenga LA, Ribeiro M, Dai L, Shiels PG, Stenvinkel P, Lindholm B, Mafra D (2021) Cruciferous vegetables: rationale for exploring potential salutary effects of sulforaphane-rich foods in patients with chronic kidney disease. Nutr Rev 79:1204\u20131224","journal-title":"Nutr Rev"},{"key":"267_CR10","doi-asserted-by":"crossref","first-page":"rs6","DOI":"10.1126\/scisignal.2003573","volume":"6","author":"P Casado","year":"2013","unstructured":"Casado P, Rodriguez-Prados J-C, Cosulich SC, Guichard S, Vanhaesebroeck B, Joel S, Cutillas PR (2013) Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells. Sci Signal 6:rs6","journal-title":"Sci Signal"},{"key":"267_CR11","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1182\/blood-2008-10-182626","volume":"113","author":"G Chan","year":"2009","unstructured":"Chan G, Kalaitzidis D, Usenko T, Kutok JL, Yang W, Mohi MG, Neel BG (2009) Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood 113:4414\u20134424","journal-title":"Blood"},{"key":"267_CR12","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1021\/bi801973z","volume":"48","author":"C-Y Chen","year":"2009","unstructured":"Chen C-Y, Willard D, Rudolph J (2009) Redox regulation of SH2-domain-containing protein tyrosine phosphatases by two backdoor cysteines. Biochemistry 48:1399\u20131409","journal-title":"Biochemistry"},{"key":"267_CR13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12959-025-00709-9","volume":"23","author":"Y Chen","year":"2025","unstructured":"Chen Y, Lin Y, Hong J, Wang J, Li B, Liu Z, Ma Y, Sun X, Wang S, Li M et al (2025) Oroxylin A reverses SHP-2 oxidative inactivation in GPVI signaling to suppress platelet activation and thrombus formation. Thromb J 23:26","journal-title":"Thromb J"},{"key":"267_CR14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","volume":"535","author":"Y-NP Chen","year":"2016","unstructured":"Chen Y-NP, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, Antonakos B, Chen CH-T, Chen Z, Cooke VG et al (2016) Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature 535:148\u2013152","journal-title":"Nature"},{"key":"267_CR15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12325-024-03018-1","volume":"42","author":"G Clack","year":"2025","unstructured":"Clack G, Moore C, Ruston L, Wilson D, Koch A, Webb D, Mallard N (2025) A phase 1 randomized, placebo-controlled study evaluating the safety, tolerability, and pharmacokinetics of enteric-coated stabilized sulforaphane (SFX-01) in male participants. Adv Ther 42:216\u2013232","journal-title":"Adv Ther"},{"key":"267_CR16","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.4161\/cc.9.23.13955","volume":"9","author":"G Dimco","year":"2010","unstructured":"Dimco G, Knight RA, Latchman DS, Stephanou A (2010) STAT1 interacts directly with cyclin D1\/Cdk4 and mediates cell cycle arrest. Cell Cycle 9:4638\u20134649","journal-title":"Cell Cycle"},{"key":"267_CR17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00431-024-05933-5","volume":"184","author":"E Dumont","year":"2024","unstructured":"Dumont E, Tiemens DK, Draaisma JMT, Kleimeier LER, van Druten D, Mulkens S (2024) Do children with a Noonan syndrome-like RASopathy and avoidant\/restrictive food intake disorder benefit from behavioral therapy?. Eur J Pediatr 184:100","journal-title":"Eur J Pediatr"},{"key":"267_CR18","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-18-0444","volume":"8","author":"C Fedele","year":"2018","unstructured":"Fedele C, Ran H, Diskin B, Wei W, Jen J, Geer MJ, Araki K, Ozerdem U, Simeone DM, Miller G et al (2018) SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models. Cancer Discov 8:1237\u20131249","journal-title":"Cancer Discov"},{"key":"267_CR19","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.TIR120.002216","volume":"20","author":"DJ Geiszler","year":"2021","unstructured":"Geiszler DJ, Kong AT, Avtonomov DM, Yu F, Leprevost FDV, Nesvizhskii AI (2021) PTM-shepherd: analysis and summarization of post-translational and chemical modifications from open search results. Mol Cell Proteom 20:100018","journal-title":"Mol Cell Proteom"},{"key":"267_CR20","first-page":"1","volume":"11","author":"AK Gupta","year":"2021","unstructured":"Gupta AK, Meena JP, Chopra A, Tanwar P, Seth R (2021) Juvenile myelomonocytic leukemia-A comprehensive review and recent advances in management. Am J Blood Res 11:1\u201321","journal-title":"Am J Blood Res"},{"key":"267_CR21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2013.03.124","volume":"524","author":"I Handy","year":"2013","unstructured":"Handy I, Patel RC (2013) STAT1 requirement for PKR-induced cell cycle arrest in vascular smooth muscle cells in response to heparin. Gene 524:15\u201321","journal-title":"Gene"},{"key":"267_CR22","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1158\/1535-7163.MCT-19-0170","volume":"18","author":"H-X Hao","year":"2019","unstructured":"Hao H-X, Wang H, Liu C, Kovats S, Velazquez R, Lu H, Pant B, Shirley M, Meyer MJ, Pu M et al (2019) Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS-mutant cancers. Mol Cancer Ther 18:2368\u20132380","journal-title":"Mol Cancer Ther"},{"key":"267_CR23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41587-019-0391-9","volume":"38","author":"M Hijazi","year":"2020","unstructured":"Hijazi M, Smith R, Rajeeve V, Bessant C, Cutillas PR (2020) Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring. Nat Biotechnol 38:493\u2013502","journal-title":"Nat Biotechnol"},{"key":"267_CR24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0092-8674(00)80938-1","volume":"92","author":"P Hof","year":"1998","unstructured":"Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE (1998) Crystal structure of the tyrosine phosphatase SHP-2. Cell 92:441\u2013450","journal-title":"Cell"},{"key":"267_CR25","doi-asserted-by":"crossref","first-page":"13.24.11","DOI":"10.1002\/0471250953.bi1324s46","volume":"46","author":"JD Holman","year":"2014","unstructured":"Holman JD, Tabb DL, Mallick P (2014) Employing proteowizard to convert raw mass spectrometry data. Curr Protoc Bioinforma 46:13.24.11\u201313.24.19","journal-title":"Curr Protoc Bioinforma"},{"key":"267_CR26","doi-asserted-by":"crossref","first-page":"v122","DOI":"10.1093\/annonc\/mdz242.036","volume":"30","author":"SJ Howell","year":"2019","unstructured":"Howell SJ, Campone M, Cort\u00e9s J, Duhoux FP, Ross S, Morris T, Franklin S (2019) 341P - final results of the STEM trial: SFX-01 in the treatment and evaluation of ER+ Her2- metastatic breast cancer (mBC). Ann Oncol 30:v122","journal-title":"Ann Oncol"},{"key":"267_CR27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1021\/tx100389r","volume":"24","author":"C Hu","year":"2011","unstructured":"Hu C, Eggler AL, Mesecar AD, van Breemen RB (2011) Modification of Keap1 cysteine residues by sulforaphane. Chem Res Toxicol 24:515\u2013521","journal-title":"Chem Res Toxicol"},{"key":"267_CR28","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1182\/blood-2008-11-191536","volume":"114","author":"GD Jack","year":"2009","unstructured":"Jack GD, Zhang L, Friedman AD (2009) M-CSF elevates c-Fos and phospho-C\/EBP\u03b1(S21) via ERK whereas G-CSF stimulates SHP2 phosphorylation in marrow progenitors to contribute to myeloid lineage specification. Blood 114:2172\u20132180","journal-title":"Blood"},{"key":"267_CR29","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/jcb.22881","volume":"111","author":"JI Kai","year":"2010","unstructured":"Kai JI, Huang WC, Tsai CC, Chang WT, Chen CL, Lin CF (2010) Glycogen synthase kinase-3\u03b2 indirectly facilitates interferon-\u03b3-induced nuclear factor-\u03baB activation and nitric oxide biosynthesis. J Cell Biochem 111:1522\u20131530","journal-title":"J Cell Biochem"},{"key":"267_CR30","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nmeth1113","volume":"4","author":"L K\u00e4ll","year":"2007","unstructured":"K\u00e4ll L, Canterbury JD, Weston J, Noble WS, MacCoss MJ (2007) Semi-supervised learning for peptide identification from shotgun proteomics datasets. Nat Methods 4:923\u2013925","journal-title":"Nat Methods"},{"key":"267_CR31","doi-asserted-by":"crossref","unstructured":"Kensler TW, Egner PA, Agyeman AS, Visvanathan K, Groopman JD, Chen J-G, Chen T-Y, Fahey JW, Talalay P (2013) Keap1\u2013Nrf2 signaling: a target for cancer prevention by sulforaphane. In: Pezzuto JM, Suh N (eds) Natural products in cancer prevention and therapy. Springer Berlin Heidelberg, Berlin, Heidelberg, pp 163\u2013177","DOI":"10.1007\/128_2012_339"},{"key":"267_CR32","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nmeth.4256","volume":"14","author":"AT Kong","year":"2017","unstructured":"Kong AT, Leprevost FV, Avtonomov DM, Mellacheruvu D, Nesvizhskii AI (2017) MSFragger: ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics. Nat Methods 14:513\u2013520","journal-title":"Nat Methods"},{"key":"267_CR33","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1182\/blood-2005-02-0531","volume":"106","author":"CP Kratz","year":"2005","unstructured":"Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergstr\u00e4sser E, Emanuel PD, Hasle H, Kardos G, Klein C, Kojima S et al (2005) The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome\/myeloproliferative disease. Blood 106:2183\u20132185","journal-title":"Blood"},{"key":"267_CR34","doi-asserted-by":"crossref","first-page":"18930","DOI":"10.1073\/pnas.0806556105","volume":"105","author":"M Krenz","year":"2008","unstructured":"Krenz M, Gulick J, Osinska HE, Colbert MC, Molkentin JD, Robbins J (2008) Role of ERK1\/2 signaling in congenital valve malformations in Noonan syndrome. Proc Natl Acad Sci USA 105:18930\u201318935","journal-title":"Proc Natl Acad Sci USA"},{"key":"267_CR35","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1161\/01.RES.0000186194.06514.b0","volume":"97","author":"M Krenz","year":"2005","unstructured":"Krenz M, Yutzey KE, Robbins J (2005) Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1\/2 signaling. Circ Res 97:813\u2013820","journal-title":"Circ Res"},{"key":"267_CR36","volume":"9","author":"JR LaRochelle","year":"2018","unstructured":"LaRochelle JR, Fodor M, Vemulapalli V, Mohseni M, Wang P, Stams T, LaMarche MJ, Chopra R, Acker MG, Blacklow SC (2018) Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition. Nat Commun 9:4508","journal-title":"Nat Commun"},{"key":"267_CR37","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.cell.2019.06.003","volume":"178","author":"L Lignitto","year":"2019","unstructured":"Lignitto L, LeBoeuf SE, Homer H, Jiang S, Askenazi M, Karakousi TR, Pass HI, Bhutkar AJ, Tsirigos A, Ueberheide B et al (2019) Nrf2 activation promotes lung cancer metastasis by inhibiting the degradation of Bach1. Cell 178:316\u2013329.e318","journal-title":"Cell"},{"key":"267_CR38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"CA Lipinski","year":"2004","unstructured":"Lipinski CA (2004) Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 1:337\u2013341","journal-title":"Drug Discov Today Technol"},{"key":"267_CR39","first-page":"00917","volume":"10","author":"MB Long","year":"2024","unstructured":"Long MB, Abo-Leyah H, Giam YH, Vadiveloo T, Hull RC, Keir HR, Pembridge T, Alferes De Lima D, Delgado L, Inglis SK et al (2024) SFX-01 in hospitalised patients with community-acquired pneumonia during the COVID-19 pandemic: a double-blind, randomised, placebo-controlled trial. ERJ Open Res 10:00917\u201302023","journal-title":"ERJ Open Res"},{"key":"267_CR40","doi-asserted-by":"crossref","first-page":"e20180853","DOI":"10.1084\/jem.20180853","volume":"218","author":"E Louka","year":"2021","unstructured":"Louka E, Povinelli B, Rodriguez-Meira A, Buck G, Wen WX, Wang G, Sousos N, Ashley N, Hamblin A, Booth CAG et al (2021) Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia. J Exp Med 218:e20180853","journal-title":"J Exp Med"},{"key":"267_CR41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1097-2765(01)00369-0","volume":"8","author":"W Lu","year":"2001","unstructured":"Lu W, Gong D, Bar-Sagi D, Cole PA (2001) Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol Cell 8:759\u2013769","journal-title":"Mol Cell"},{"key":"267_CR42","doi-asserted-by":"crossref","first-page":"8313","DOI":"10.1021\/acsomega.7b01318","volume":"2","author":"LESF Machado","year":"2017","unstructured":"Machado LESF, Critton DA, Page R, Peti W (2017) Redox regulation of a gain-of-function mutation (N308D) in SHP2 Noonan syndrome. ACS Omega 2:8313\u20138318","journal-title":"ACS Omega"},{"key":"267_CR43","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/s41591-018-0023-9","volume":"24","author":"S Mainardi","year":"2018","unstructured":"Mainardi S, Mulero-S\u00e1nchez A, Prahallad A, Germano G, Bosma A, Krimpenfort P, Lieftink C, Steinberg JD, de Wit N, Gon\u00e7alves-Ribeiro S et al (2018) SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Nat Med 24:961\u2013967","journal-title":"Nat Med"},{"key":"267_CR44","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1158\/0008-5472.CAN-09-0913","volume":"69","author":"CP Masamha","year":"2009","unstructured":"Masamha CP, Benbrook DM (2009) Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res 69:6565\u20136572","journal-title":"Cancer Res"},{"key":"267_CR45","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/j.1349-7006.2009.01257.x","volume":"100","author":"T Matozaki","year":"2009","unstructured":"Matozaki T, Murata Y, Saito Y, Okazawa H, Ohnishi H (2009) Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci 100:1786\u20131793","journal-title":"Cancer Sci"},{"key":"267_CR46","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00431-019-03468-8","volume":"179","author":"Y Miao","year":"2020","unstructured":"Miao Y, Li B, Ding L, Zhu H, Luo C, Wang J, Luo C, Chen J (2020) PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center. Eur J Pediatr 179:463\u2013472","journal-title":"Eur J Pediatr"},{"key":"267_CR47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.gde.2006.12.011","volume":"17","author":"MG Mohi","year":"2007","unstructured":"Mohi MG, Neel BG (2007) The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev 17:23\u201330","journal-title":"Curr Opin Genet Dev"},{"key":"267_CR48","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ymeth.2011.02.004","volume":"54","author":"A Montoya","year":"2011","unstructured":"Montoya A, Beltran L, Casado P, Rodr\u00edguez-Prados JC, Cutillas PR (2011) Characterization of a TiO\u2082 enrichment method for label-free quantitative phosphoproteomics. Methods 54:370\u2013378","journal-title":"Methods"},{"key":"267_CR49","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI30756","volume":"117","author":"T Nakamura","year":"2007","unstructured":"Nakamura T, Colbert M, Krenz M, Molkentin JD, Hahn HS, Dorn 2ndGW, Robbins J (2007) Mediating ERK 1\/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J Clin Invest 117:2123\u20132132","journal-title":"J Clin Invest"},{"key":"267_CR50","volume":"14","author":"W Qiu","year":"2014","unstructured":"Qiu W, Wang X, Romanov V, Hutchinson A, Lin A, Ruzanov M, Battaile KP, Pai EF, Neel BG, Chirgadze NY (2014) Structural insights into Noonan\/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11). BMC Struct Biol 14:10","journal-title":"BMC Struct Biol"},{"key":"267_CR51","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.onc.1201920","volume":"17","author":"CK Qu","year":"1998","unstructured":"Qu CK, Feng GS (1998) Shp-2 has a positive regulatory role in ES cell differentiation and proliferation. Oncogene 17:433\u2013439","journal-title":"Oncogene"},{"key":"267_CR52","doi-asserted-by":"crossref","first-page":"101477","DOI":"10.1016\/j.jbc.2021.101477","volume":"298","author":"D Raveendra-Panickar","year":"2022","unstructured":"Raveendra-Panickar D, Finlay D, Layng FI, Lambert LJ, Celeridad M, Zhao M, Barbosa K, De Backer LJS, Kwong E, Gosalia P et al (2022) Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells. J Biol Chem 298:101477","journal-title":"J Biol Chem"},{"key":"267_CR53","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1542\/peds.2009-3207","volume":"126","author":"AA Romano","year":"2010","unstructured":"Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, Roberts AE, Robinson W, Takemoto CM, Noonan JA (2010) Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 126:746\u2013759","journal-title":"Pediatrics"},{"key":"267_CR54","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-018-0024-8","volume":"24","author":"DA Ruess","year":"2018","unstructured":"Ruess DA, Heynen GJ, Ciecielski KJ, Ai J, Berninger A, Kabacaoglu D, G\u00f6rg\u00fcl\u00fc K, Dantes Z, W\u00f6rmann SM, Diakopoulos KN et al (2018) Mutant KRAS-driven cancers depend on PTPN11\/SHP2 phosphatase. Nat Med 24:954\u2013960","journal-title":"Nat Med"},{"key":"267_CR55","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/adc.81.1.28","volume":"81","author":"N Shah","year":"1999","unstructured":"Shah N, Rodriguez M, Louis DS, Lindley K, Milla PJ (1999) Feeding difficulties and foregut dysmotility in Noonan\u2019s syndrome. Arch Dis Child 81:28\u201331","journal-title":"Arch Dis Child"},{"key":"267_CR56","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41375-018-0020-5","volume":"32","author":"X Sun","year":"2018","unstructured":"Sun X, Ren Y, Gunawan S, Teng P, Chen Z, Lawrence HR, Cai J, Lawrence NJ, Wu J (2018) Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 32:1246\u20131249","journal-title":"Leukemia"},{"key":"267_CR57","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ng772","volume":"29","author":"M Tartaglia","year":"2001","unstructured":"Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S et al (2001) Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29:465\u2013468","journal-title":"Nat Genet"},{"key":"267_CR58","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.freeradbiomed.2007.03.021","volume":"43","author":"I Weibrecht","year":"2007","unstructured":"Weibrecht I, B\u00f6hmer S-A, Dagnell M, Kappert K, \u00d6stman A, B\u00f6hmer F-D (2007) Oxidation sensitivity of the catalytic cysteine of the protein-tyrosine phosphatases SHP-1 and SHP-2. Free Radic Biol Med 43:100\u2013110","journal-title":"Free Radic Biol Med"},{"key":"267_CR59","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/emboj\/16.6.1291","volume":"16","author":"AH-T Wong","year":"1997","unstructured":"Wong AH-T, Tam NWN, Yang Y-L, Cuddihy AR, Li S, Kirchhoff S, Hauser H, Decker T, Koromilas AE (1997) Physical association between STAT1 and the interferon-inducible protein kinase PKR and implications for interferon and double-stranded RNA signaling pathways. EMBO J 16:1291\u20131304","journal-title":"EMBO J"},{"key":"267_CR60","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1182\/blood-2010-01-265652","volume":"116","author":"D Xu","year":"2010","unstructured":"Xu D, Wang S, Yu W-M, Chan G, Araki T, Bunting KD, Neel BG, Qu C-K (2010) A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells. Blood 116:3611\u20133621","journal-title":"Blood"},{"key":"267_CR61","doi-asserted-by":"crossref","first-page":"e90220","DOI":"10.1172\/jci.insight.90220","volume":"1","author":"JS Yi","year":"2016","unstructured":"Yi JS, Huang Y, Kwaczala AT, Kuo IY, Ehrlich BE, Campbell SG, Giordano FJ, Bennett AM (2016) Low-dose dasatinib rescues cardiac function in Noonan syndrome. JCI Insight 1:e90220","journal-title":"JCI Insight"},{"key":"267_CR62","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1128\/MCB.19.3.2416","volume":"19","author":"M You","year":"1999","unstructured":"You M, Yu DH, Feng GS (1999) Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak\/STAT pathway. Mol Cell Biol 19:2416\u20132424","journal-title":"Mol Cell Biol"},{"key":"267_CR63","volume":"20","author":"F Yu","year":"2021","unstructured":"Yu F, Haynes SE, Nesvizhskii AI (2021) IonQuant enables accurate and sensitive label-free quantification with FDR-controlled match-between-runs. Mol Cell Proteom 20:100077","journal-title":"Mol Cell Proteom"},{"key":"267_CR64","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1158\/1940-6207.CAPR-24-0386","volume":"18","author":"JM Yuan","year":"2025","unstructured":"Yuan JM, Kensler TW, Dacic S, Hartman DJ, Wang R, Balogh PA, Sufka P, Turner MA, Fuhrer K, Seigh L et al (2025) Randomized phase II clinical trial of sulforaphane in former smokers at high risk for lung cancer. Cancer Prev Res 18:335\u2013345","journal-title":"Cancer Prev Res"},{"key":"267_CR65","doi-asserted-by":"crossref","first-page":"11368","DOI":"10.1021\/acs.jmedchem.0c00249","volume":"63","author":"X Yuan","year":"2020","unstructured":"Yuan X, Bu H, Zhou J, Yang C-Y, Zhang H (2020) Recent advances of SHP2 inhibitors in cancer therapy: current development and clinical application. J Med Chem 63:11368\u201311396","journal-title":"J Med Chem"},{"key":"267_CR66","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/jcmm.12618","volume":"19","author":"J Zhang","year":"2015","unstructured":"Zhang J, Zhang F, Niu R (2015) Functions of Shp2 in cancer. J Cell Mol Med 19:2075\u20132083","journal-title":"J Cell Mol Med"},{"key":"267_CR67","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1073\/pnas.89.6.2399","volume":"89","author":"Y Zhang","year":"1992","unstructured":"Zhang Y, Talalay P, Cho CG, Posner GH (1992) A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci USA 89:2399\u20132403","journal-title":"Proc Natl Acad Sci USA"},{"key":"267_CR68","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1006\/abio.1996.0311","volume":"239","author":"Y Zhang","year":"1996","unstructured":"Zhang Y, Wade KL, Prestera T, Talalay P (1996) Quantitative determination of isothiocyanates, dithiocarbamates, carbon disulfide, and related thiocarbonyl compounds by cyclocondensation with 1,2-benzenedithiol. Anal Biochem 239:160\u2013167","journal-title":"Anal Biochem"},{"key":"267_CR69","doi-asserted-by":"crossref","first-page":"578315","DOI":"10.3389\/fonc.2020.578315","volume":"10","author":"J Zhao","year":"2020","unstructured":"Zhao J, Lin X, Meng D, Zeng L, Zhuang R, Huang S, Lv W, Hu J (2020) Nrf2 mediates metabolic reprogramming in non-small cell lung cancer. Front Oncol 10:578315","journal-title":"Front Oncol"},{"issue":"4","key":"267_CR70","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12975-024-01278-1","volume":"16","author":"A Zolnourian","year":"2024","unstructured":"Zolnourian A, Garland P, Holton P, Arora M, Rhodes J, Uff C, Birch T, Howat D, Franklin S, Galea I et al (2024) A randomised controlled trial of SFX-01 After subarachnoid haemorrhage\u2014the SAS study. Transl Stroke Res 16(4):1031\u20131043","journal-title":"Transl Stroke Res"},{"key":"267_CR71","doi-asserted-by":"crossref","first-page":"e028514","DOI":"10.1136\/bmjopen-2018-028514","volume":"10","author":"AH Zolnourian","year":"2020","unstructured":"Zolnourian AH, Franklin S, Galea I, Bulters DO (2020) Study protocol for SFX-01 after subarachnoid haemorrhage (SAS): a multicentre randomised double-blinded, placebo controlled trial. BMJ Open 10:e028514","journal-title":"BMJ Open"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-025-00267-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-025-00267-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-025-00267-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:28:43Z","timestamp":1786984123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-025-00267-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":71,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,11]]}},"alternative-id":["267"],"URL":"https:\/\/doi.org\/10.1038\/s44321-025-00267-7","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"4 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. PE acknowledges he was an unpaid advisor to Theracryf plc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}],"article-number":"11"}}